Literature DB >> 2889495

The Scottish First Episode Schizophrenia Study. II. Treatment: pimozide versus flupenthixol. The Scottish Schizophrenia Research Group.

.   

Abstract

In a randomised double-blind study, 46 first episode schizophrenics were given pimozide or flupenthixol for up to 5 weeks; the mean daily dose at the end was 18.8 mg pimozide and 20 mg flupenthixol. There were no significant between-drug differences in the effect on mental state or behaviour; positive schizophrenic symptoms responded to treatment, negative symptoms did not. Most patients required anti-Parkinsonian medication. Poor response was associated with 'organicity'. A switch to maintenance therapy after 5 weeks, the outcome of successful treatment and patient cooperation, was achieved in only 54%. There was no relationship between plasma prolactin levels and severity of schizophrenic symptoms in unmedicated patients. Pimozide produced greater elevation of plasma prolactin. Plasma neuroleptic levels showed drug compliance was satisfactory throughout in only 54%.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2889495     DOI: 10.1192/bjp.150.3.334

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  8 in total

1.  Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Authors:  Natalie C Edwards; Julie C Locklear; Marcia F T Rupnow; Ronald J Diamond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 2.  Early intervention for psychosis.

Authors:  Max Marshall; John Rathbone
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 3.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

4.  Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.

Authors:  Natalie C Edwards; Marcia F T Rupnow; Chris L Pashos; Marc F Botteman; Ronald J Diamond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 6.  Pharmacological management of first-episode schizophrenia and related nonaffective psychoses.

Authors:  Daniel W Bradford; Diana O Perkins; Jeffrey A Lieberman
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  One-year follow-up of patients with first-episode schizophrenia (comparison between remitters and non-remitters).

Authors:  Eva Cesková; Prikryl Radovan; Kaspárek Tomás; Kucerová Hana
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

Review 8.  Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders.

Authors:  Jataveda Mahapatra; Seema N Quraishi; Anthony David; Stephanie Sampson; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2014-06-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.